Daum Severin, Sahin Ergün, Jansen Andreas, Heine Bernhard, Riecken Ernst-Otto, Zeitz Martin, Schmidt Wolfgang
Department of Medicine I, Gastroenterology, Infectious Diseases and Rheumatology, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany.
Digestion. 2003;68(2-3):86-90. doi: 10.1159/000074520. Epub 2003 Oct 24.
Autoimmune enteropathy is a life-threatening, chronic disease of the small bowel mucosa, which generally responds well to steroids. Treatment requires long-term immunosuppression, and steroid-sparing treatment strategies are desirable. Azathioprine and cyclosporine A have limitations, however alternatives have not been described in adults.
We present the case of a 54-year-old male patient with autoimmune enteropathy who responded initially to a standard treatment with steroids, but was dependent on 30 mg prednisolone. Medical treatment was changed to tacrolimus after renal function deteriorated under treatment with cyclosporine A. Under this regimen, small bowel histology normalized and the clinical condition is stable after 2 years of introduction of tacrolimus.
This constitutes the first report of effective treatment of adult autoimmune enteropathy with tacrolimus, a substance with a similar mode of action to cyclosporine, but with fewer side effects and improved bioavailability.
自身免疫性肠病是一种危及生命的小肠黏膜慢性疾病,通常对类固醇治疗反应良好。治疗需要长期免疫抑制,因此需要采用减少类固醇用量的治疗策略。硫唑嘌呤和环孢素A存在局限性,然而,针对成人患者的替代治疗方法尚未见报道。
我们报告了一例54岁男性自身免疫性肠病患者,该患者最初对类固醇标准治疗有反应,但依赖30毫克泼尼松龙。在用环孢素A治疗期间肾功能恶化后,将药物治疗改为他克莫司。在该治疗方案下,小肠组织学恢复正常,在引入他克莫司2年后临床状况稳定。
这是关于他克莫司有效治疗成人自身免疫性肠病的首例报告,他克莫司与环孢素作用方式相似,但副作用更少,生物利用度更高。